Previous close | 2.3000 |
Open | 2.3200 |
Bid | 2.4500 x 200 |
Ask | 2.4800 x 200 |
Day's range | 2.3100 - 2.4800 |
52-week range | 1.6700 - 5.2500 |
Volume | |
Avg. volume | 172,198 |
Market cap | 99.677M |
Beta (5Y monthly) | 1.82 |
PE ratio (TTM) | 17.57 |
EPS (TTM) | 0.1400 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.25 |
PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has paid off the remaining balance of approx. $1,300,000 under the convertible debentures (the “Convertible Debentures”) previously issued and sold to YA II PN, Ltd. (“Yorkville”) in March 2023. Sci
Oramed Pharmaceuticals ( NASDAQ:ORMP ) Full Year 2023 Results Key Financial Results Net income: US$5.53m (up from...
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.